Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.

ABSTRACT:

Objective

Plasma phosphorylated-tau-181 (p-tau181) reliably detects clinical Alzheimer's disease (AD) as well as asymptomatic amyloid-β (Aβ) pathology, but is consistently quantified with assays using antibody AT270, which cross-reacts with p-tau175. This study investigates two novel phospho-specific assays for plasma p-tau181 and p-tau231 in clinical and asymptomatic AD.

Methods

Plasma p-tau species were quantified with Simoa in 44 AD patients, 40 spouse controls and an independent cohort of 151 cognitively unimpaired (CU) elderly who underwent Aβ-PET. Simoa plasma Aβ42 measurements were available in a CU subset (N = 69). Receiver operating characteristics and Aβ-PET associations were used to evaluate biomarker validity.

Results

The novel plasma p-tau181 and p-tau231

SUBMITTER: De Meyer S 

PROVIDER: S-EPMC9082389 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature